应用欧盟监管框架来确定迷幻药的利益风险概况
Kate Browne1, Ewa Bałkowiec-Iskra2,3,4, Andre Elferink4,5
1Stakeholders and Communication Division, European Medicines Agency, 1083 HS Amsterdam, Netherlands.
欧盟对迷幻药物的监管批准需要严格的临床试验证据. 关键的挑战包括管理参与者盲目化,预期效应,以及为可靠的利益风险评估定义精确的试验人群.
科学领域:
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
- 监管科学 监管科学
背景情况:
- 迷幻药显示治疗潜力,但对临床试验构成独特的方法学挑战.
- 欧盟 (EU) 的营销许可要求遵守所有药品的严格监管标准.
研究的目的:
- 介绍欧洲药物管理局关于心理药物批准知识缺口的观点.
- 概述设计可靠的心理学疗法临床试验的挑战.
主要方法:
- 欧洲药品署于2024年4月召开的一场多方利益相关者研讨会.
- 讨论药品的监管要求和证据标准.
主要成果:
- 确定了关键的挑战:功能失明,预期和nocebo效应.
- 强调需要将试验人群与治疗指示对齐,以实现概括性.
- 突出了描述剂量反应关系和主观体验相关性的重要性.
结论:
- 强有力的证据生成对于心理药物监管决策至关重要.
- 解决试验设计,安全分析和伦理考虑中的方法论挑战是必不可少的.
- 需要仔细考虑心理支持整合和风险减轻策略.
更多相关视频
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
08:56Detection of Regulated Ergot Alkaloids in Food Matrices by Liquid Chromatography-Trapped Ion Mobility Spectrometry-Time-of-Flight Mass Spectrometry
Published on: November 22, 2024
相关概念视频
Hallucinogens and Psychedelics
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
Drug Regulation
Drug Control Governance: Regulatory Bodies and Their Impact
CNS Stimulants: Psychedelic Agents
An Overview of Psychoactive Drugs
Stimulants such as cocaine, amphetamines, and nicotine enhance brain activity, leading to increased alertness, attention, and energy. These drugs typically raise heart rate, blood pressure, and body temperature. While they can induce feelings of euphoria, their misuse can result in severe health...
Psychosurgery
Historical Development of Psychosurgery
In the 1930s, Portuguese neurologist Antonio Egas Moniz introduced a surgical procedure designed...
